Advertisement
Advertisement
Trending on Urology Times
1
Metabolic syndrome frequent during first year of ADT-ARPI therapy for prostate cancer
2
Defining High-Risk NMIBC and Diagnostic Gaps Before Referral
3
Emanuele Crupi, MD, highlights phase 2 trial of GemFLP in urinary tract adenocarcinomas
4
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
5